The effect of β-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes

Toxicology Letters

Volumn 195, Issue 2-3, 2010, Pages 147-154

  Elsherbiny, Marwa E ^a   El Kadi, Ayman O S ^a   Brocks, Dion R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amiodarone toxicity; CYP1A; Cytochrome P450; Gene expression; Induction; Polycyclic aromatic hydrocarbons

Indexed keywords

AMIODARONE; BETA NAPHTHOFLAVONE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DEETHYLAMIODARONE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HEART; INTESTINE MUCOSA; KIDNEY MICROSOME; KIDNEY PARENCHYMA; LIVER MICROSOME; LIVER PARENCHYMA; LUNG PARENCHYMA; LUNG TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BETA-NAPHTHOFLAVONE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; KIDNEY; LUNG; MALE; MICROSOMES; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 77952548050     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.03.019     Document Type: Article

References (67)

1. Anonymous Environmental Health Criteria 202. Selected Non-heterocyclic Polycyclic Aromatic Hydrocarbons 1998, World Health Organization.
2. Barakat M.M., El-Kadi A.O., du Souich P. L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci. 2001, 69:1559-1571.
3. Bargout R., Jankov A., Dincer E., Wang R., Komodromos T., Ibarra-Sunga O., Filippatos G., Uhal B.D. Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 278:L1039-1044.
4. Batcher E.L., Tang X.C., Singh B.N., Singh S.N., Reda D.J., Hershman J.M. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am. J. Med. 2007, 120:880-885.
5. Beddows S.A., Page S.R., Taylor A.H., McNerney R., Whitley G.S., Johnstone A.P., Nussey S.S. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem. Pharmacol. 1989, 38:4397-4403.
6. Bolt M.W., Card J.W., Racz W.J., Brien J.F., Massey T.E. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J. Pharmacol. Exp. Ther. 2001, 298:1280-1289.
7. Brien J.F., Jimmo S., Brennan F.J., Ford S.E., Armstrong P.W. Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can. J. Physiol. Pharmacol. 1987, 65:360-364.
8. Castorena-Torres F., Bermudez de Leon M., Cisneros B., Zapata-Perez O., Salinas J.E., Albores A. Changes in gene expression induced by polycyclic aromatic hydrocarbons in the human cell lines HepG2 and A549. Toxicol. In Vitro 2008, 22:411-421.
9. Chen Y.Y., Chen C.Y., Leung K.K. Acute pancreatitis and amiodarone: a case report. World J. Gastroenterol. 2007, 13:975-977.
10. Debri K., Boobis A.R., Davies D.S., Edwards R.J. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem. Pharmacol. 1995, 50:2047-2056.
11. Elsherbiny M., El-Kadi A., Brocks D. Assessment of the inactivation potential of desethylamiodarone on human CYP1A1. Drug Metab. Lett. 2010, 4(1):9-14.
12. Elsherbiny M.E., Brocks D.R. The effect of CYP1A induction on amiodarone disposition in the rat. J. Pharm. Sci. 2010, 99(1):539-548.
13. Elsherbiny M.E., El-Kadi A.O., Brocks D.R. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J. Pharm. Pharm. Sci. 2008, 11:147-159.
14. Ernawati D.K., Stafford L., Hughes J.D. Amiodarone-induced pulmonary toxicity. Br. J. Clin. Pharmacol. 2008, 66:82-87.
15. Fabre G., Julian B., Saint-Aubert B., Joyeux H., Berger Y. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 1993, 21:978-985.
16. Fanta S., Jonsson S., Backman J.T., Karlsson M.O., Hoppu K. Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates. Br. J. Clin. Pharmacol. 2007, 64:772-784.
17. Fontana R.J., Lown K.S., Paine M.F., Fortlage L., Santella R.M., Felton J.S., Knize M.G., Greenberg A., Watkins P.B. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999, 117:89-98.
18. Ha H.R., Bigler L., Binder M., Kozlik P., Stieger B., Hesse M., Altorfer H.R., Follath F. Metabolism of amiodarone (part I): identification of a new hydroxylated metabolite of amiodarone. Drug Metab. Dispos. 2001, 29:152-158.
19. Hamdy D.A., Brocks D.R. Experimental hyperlipidemia causes an increase in the electrocardiographic changes associated with amiodarone. J. Cardiovasc. Pharmacol. 2009, 53(1):1-8.
20. Holt D.W., Tucker G.T., Jackson P.R., Storey G.C. Amiodarone pharmacokinetics. Am. Heart J. 1983, 106:840-847.
21. Iba M.M., Fung J., Thomas P.E., Park Y. Constitutive and induced expression by pyridine and beta-naphthoflavone of rat CYP1A is sexually dimorphic. Arch. Toxicol. 1999, 73:208-216.
22. Jarand J., Lee A., Leigh R. Amiodaronoma: an unusual form of amiodarone-induced pulmonary toxicity. CMAJ 2007, 176:1411-1413.
23. Johnson T.N., Tucker G.T., Tanner M.S., Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005, 11:1481-1493.
24. Jun A.S., Brocks D.R. High-performance liquid chromatography assay of amiodarone in rat plasma. J. Pharm. Pharm. Sci. 2001, 4:263-268.
25. Kannan R., Sarma J.S., Guha M., Venkataraman K. Tissue drug accumulation and ultrastructural changes during amiodarone administration in rats. Fundam. Appl. Toxicol. 1989, 13:793-803.
26. Karhunen P.J., Penttila A. Preneoplastic lesions of human liver. Hepatogastroenterology 1987, 34:10-15.
27. Korashy H.M., Elbekai R.H., El-Kadi A.O. Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review. Xenobiotica 2004, 34:1-29.
28. Kushinsky R., Louis C.J. The effect of cigarette smoke on aryl hydrocarbon hydroxylase activity and cytochrome P450 content in rat liver and lung microsomes. Oncology 1976, 33:197-200.
29. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods 2001, 25:402-408.
30. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
31. Lupp A., Danz M., Muller D. Morphology and cytochrome P450 isoforms expression in precision-cut rat liver slices. Toxicology 2001, 161:53-66.
32. Lupp A., Danz M., Muller D. Histomorphological changes and cytochrome P450 isoforms expression and activities in precision-cut liver slices from neonatal rats. Toxicology 2005, 206:427-438.
33. Meng X., Mojaverian P., Doedee M., Lin E., Weinryb I., Chiang S.T., Kowey P.R. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am. J. Cardiol. 2001, 87:432-435.
34. Mitschke D., Reichel A., Fricker G., Moenning U. Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab. Dispos. 2008, 36:1039-1045.
35. Naccarelli G.V., Wolbrette D.L., Dell'Orfano J.T., Patel H.M., Luck J.C. Amiodarone: what have we learned from clinical trials?. Clin. Cardiol. 2000, 23:73-82.
36. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27:1350-1359.
37. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos. 2000, 28:1303-1310.
38. Ohyama K., Nakajima M., Suzuki M., Shimada N., Yamazaki H., Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 2000, 49:244-253.
39. Okayasu K., Takeda Y., Kojima J., Yoshizawa A., Kobayashi N., Sugiyama H., Kudo K. Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. Intern. Med. 2006, 45:1303-1307.
40. Piccini J.P., Hasselblad V., Peterson E.D., Washam J.B., Califf R.M., Kong D.F. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Cardiol. 2009, 54:1089-1095.
41. Pollak P.T. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am. J. Cardiol. 1999, 84:37R-45R.
42. Puli S.R., Fraley M.A., Puli V., Kuperman A.B., Alpert M.A. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am. J. Med. Sci. 2005, 330:257-261.
43. Rafeiro E., Leeder R.G., Daniels J.M., Brien J.F., Massey T.E. In vitro hepatic, renal, and pulmonary N-dealkylation of amiodarone. Biochem. Pharmacol. 1990, 39:1627-1629.
44. Rotmensch H.H., Belhassen B., Swanson B.N., Shoshani D., Spielman S.R., Greenspon A.J., Greenspan A.M., Vlasses P.H., Horowitz L.N. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann. Intern. Med. 1984, 101:462-469.
45. Scalori A., Tavani A., Gallus S., La Vecchia C., Colombo M. Risk factors for focal nodular hyperplasia of the liver: an Italian case-control study. Am. J. Gastroenterol. 2002, 97:2371-2373.
46. Schaaf G.J., de Groene E.M., Maas R.F., Commandeur J.N., Fink-Gremmels J. Characterization of biotransformation enzyme activities in primary rat proximal tubular cells. Chem. Biol. Interact. 2001, 134:167-190.
47. Seki S., Itagaki S., Kobayashi M., Hirano T., Iseki K. Amiodarone increases the accumulation of DEA in a human alveolar epithelium-derived cell line. Biol. Pharm. Bull. 2008, 31:1449-1452.
48. Shayeganpour A., El-Kadi A.O., Brocks D.R. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms. Drug Metab. Dispos. 2006, 34:43-50.
49. Shayeganpour A., Korashy H., Patel J.P., El-Kadi A.O., Brocks D.R. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int. J. Pharm. 2008, 361:78-86.
50. Shayeganpour A., Somayaji V., Brocks D.R. A liquid chromatography-mass spectrometry assay method for simultaneous determination of amiodarone and desethylamiodarone in rat specimens. Biomed. Chromatogr. 2007, 21:284-290.
51. Shimada T., Yamazaki H., Mimura M., Wakamiya N., Ueng Y.F., Guengerich F.P., Inui Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 1996, 24:515-522.
52. Sinal C.J., Webb C.D., Bend J.R. Differential in vivo effects of alpha-naphthoflavone and beta-naphthoflavone on CYP1A1 and CYP2E1 in rat liver, lung, heart, and kidney. J. Biochem. Mol. Toxicol. 1999, 13:29-40.
53. Snider M., Kalbfleisch S., Carnes C.A. Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review. Clin. Ther. 2009, 31:1209-1218.
54. Somani P., Bandyopadhyay S., Klaunig J.E., Gross S.A. Amiodarone- and desethylamiodarone-induced myelinoid inclusion bodies and toxicity in cultured rat hepatocytes. Hepatology 1990, 11:81-92.
55. Stark G., Stark U., Windisch M., Vicenzi M., Eggenreich U., Nagl S., Kral K., Pilger E., Tritthart H.A. Comparison of acute electrophysiological effects of amiodarone and its metabolite desethylamiodarone in Langendorff perfused guinea pig hearts. Basic Res. Cardiol. 1991, 86:136-147.
56. Straif K., Baan R., Grosse Y., Secretan B., El Ghissassi F., Cogliano V. Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol. 2005, 6:931-932.
57. Thum T., Borlak J. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br. J. Pharmacol. 2000, 130:1745-1752.
58. Thum T., Erpenbeck V.J., Moeller J., Hohlfeld J.M., Krug N., Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ. Health Perspect. 2006, 114:1655-1661.
59. Torronen R., Nousiainen U., Hanninen O. Induction of aldehyde dehydrogenase by polycyclic aromatic hydrocarbons in rats. Chem. Biol. Interact. 1981, 36:33-44.
60. Trivier J.M., Libersa C., Belloc C., Lhermitte M. Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report). Life Sci. 1993, 52:PL91-96.
61. Tsuchiya Y., Nakajima M., Itoh S., Iwanari M., Yokoi T. Expression of aryl hydrocarbon receptor repressor in normal human tissues and inducibility by polycyclic aromatic hydrocarbons in human tumor-derived cell lines. Toxicol. Sci. 2003, 72:253-259.
62. Venkatakrishnan K., von Moltke L.L., Obach R.S., Greenblatt D.J. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr. Drug Metab. 2003, 4:423-459.
63. Waldhauser K.M., Torok M., Ha H.R., Thomet U., Konrad D., Brecht K., Follath F., Krahenbuhl S. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 2006, 319:1413-1423.
64. Yan Z., Caldwell G.W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 2001, 1:403-425.
65. Young R.A., Mehendale H.M. In vitro metabolism of amiodarone by rabbit and rat liver and small intestine. Drug Metab. Dispos. 1986, 14:423-429.
66. Zatloukalova J., Svihalkova-Sindlerova L., Kozubik A., Krcmar P., Machala M., Vondracek J. beta-Naphthoflavone and 3′-methoxy-4′-nitroflavone exert ambiguous effects on Ah receptor-dependent cell proliferation and gene expression in rat liver 'stem-like' cells. Biochem. Pharmacol. 2007, 73:1622-1634.
67. Zordoky B.N., El-Kadi A.O. H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J. Pharmacol. Toxicol. Methods 2007, 56:317-322.